Review article

Letting the little light of mind shine: Advances and future directions in neurochemical detection

Nikki Tjahjono a, Yihan Jin b, Alice Hsu c, Michael Roukes d, Lin Tian e, *

a Biomedical Engineering Graduate Group, University of California, Davis, Davis, CA, 95616, USA
b Neuroscience Graduate Group, University of California, Davis, Davis, CA, 95618, USA
c Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, USA
d Department of Physics, California Institute of Technology, Pasadena, CA, 91125, USA
e Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, Davis, CA, 95616, USA

ARTICLE INFO

Keywords:
neurochemistry
microdialysis
voltammetry
genetically encoded indicators
biosensors

ABSTRACT

Synaptic transmission via neurochemical release is the fundamental process that integrates and relays encoded information in the brain to regulate physiological function, cognition, and emotion. To unravel the biochemical, biophysical, and computational mechanisms of signal processing, one needs to precisely measure the neurochemical release dynamics with molecular and cell-type specificity and high resolution. Here we reviewed the development of analytical, electrochemical, and fluorescence imaging approaches to detect neurotransmitter and neuromodulator release. We discussed the advantages and practicality in implementation of each technology for ease-of-use, flexibility for multimodal studies, and challenges for future optimization. We hope this review will provide a versatile guide for tool engineering and applications for recording neurochemical release.

1. Introduction

Neuronal communication in the mammalian nervous system is governed by local and global changes in brain chemistry. Dysfunction in the complex spatiotemporal regulation of brain chemistry is associated with neurological diseases (Sarter et al., 2007). A comprehensive understanding of chemical dynamics in the diseased and healthy brain would greatly facilitate the discovery of targeted treatments that are safe and effective.

The tools available to neurobiologists to monitor chemical dynamics in the brain should have desired properties in terms of molecular specificity, sensitivity, and resolution to reveal the emergent properties of release. (Fig. 1). For example, high chemical selectivity and specificity is needed to identify and monitor specific chemical species within the brain’s complex chemical environment. A tool that can monitor a wide variety of spatial scales is ideal to gain cellular and subcellular resolution on neurotransmitter release and spillover as well as population dynamics. Also, these tools should have temporal resolution that allows for measurement of the diverse timescales at play in chemical transmission. Considering the limitations of diffusion and geometry in the extracellular space (Pal, 2018), tools with an appropriate dynamic range that permit a low limit of detection and do not saturate at high concentrations would be necessary. Finally, these tools should be minimally invasive and permit chronic recording in a variety of brain regions.

Technology breakthrough in analytical chemistry, protein engineering, and optics has led to the development of a toolkit of sensors and probes for real-time monitoring of neurochemical release dynamics. Microdialysis involves implanting a probe that contains a semi-permeable membrane over which dialysate is collected from the brain interstitial space and chemically analyzed. Electrochemical detection via fast-scan cyclic voltammetry (FSCV) is another significant advance in neurochemical monitoring that allows for sensitive detection of electroactive compounds with high temporal resolution. The development of fluorescent genetically-encoded or non-genetically encoded indicators in the past few decades have been an important advance for measuring neural activity.

* Corresponding author.
E-mail address: lintian@ucdavis.edu (L. Tian).

https://doi.org/10.1016/j.neures.2021.11.012
Received 15 September 2021; Received in revised form 12 November 2021; Accepted 19 November 2021
Available online 30 November 2021
0168-0102/© 2021 Elsevier B.V. and Japan Neuroscience Society. All rights reserved.
2. Analytical methods

2.1. Basic Principles and Advantages of Microdialysis

Microdialysis is one of the most widely used methods for monitoring neurochemicals in vivo. The concept of using dialysis to collect analytes from interstitial fluid in the brain was first reported as early as 1966, where Bito et al. inserted dialysis bags into the cortices of dogs to collect amino acids present in brain interstitial fluid (Bito et al., 1966). Since this initial study, the development of dialysis probes for the active perfusion and collection of dialysate has laid the ground work for modern-day microdialysis (Ungerstedt and Pycock, 1974). Microdialysis probes consist of a shaft housing inlet and outlet tubes that deliver fluids to and from a semi-permeable membrane (Fig. 2). The inlet tube is connected to a perfusion system that delivers perfusion fluid of physiologic solute concentrations through the probe, commonly artificial cerebrospinal fluid (aCSF) or Ringer’s solution, matching the electrolyte concentration of the brain interstitial fluid (Chen et al., 1997; Zapata et al., 2009). The perfusion fluid then flows through a semi-permeable membrane of defined molecular weight cut-off across which extracellular analytes can diffuse. The dialysate flows through the outlet tube where fractions are collected for post hoc chemical analysis. Chemical analysis of the dialysate is often done by electrochemical detection, mass spectrometry (MS), high-performance liquid chromatography (HPLC), or enzymatic detection (Jin et al., 2008; Zestos and Kennedy, 2017).

A critical advantage of microdialysis over the other techniques discussed in this review is its ability to monitor many different analytes simultaneously with picomolar range sensitivity in vivo (Ballini et al., 2008; Reinhoud et al., 2013; Yang et al., 2013). The collected samples can be analyzed using HPLC or mass spectrometry, and up to 70 different neurochemical compounds can be detected in a single dialysate sample (Wong et al., 2016). As a direct sampling method, it permits the measurement of basal concentrations of brain analytes in addition to dynamic changes in neurochemical levels. The collection of analytes by microdialysis is governed by passive diffusion (Fick’s first law) of extracellular solutes through the dialysis membrane. At standard flow rates (0.3 to 3 μL/min), microdialysis probes do not achieve absolute equilibrium with the interstitial fluid. Therefore, 100% recovery of solutes from the brain is rarely achieved, and calibration is needed to relate experimental dialysate concentrations to absolute extracellular concentrations. Many factors contribute to a microdialysis system’s efficiency of recovery (or relative recovery) for a particular analyte of interest, including flow rate, membrane surface area, analyte diffusion coefficients, and diffusion (penetration) distance (Bungay et al., 1990; Chefer et al., 2009). However, improving many of these dialysate collection parameters come with trade-offs in spatiotemporal resolution and invasiveness (brief discussion below). Probe membranes generally have molecular weight cutoffs of 20 to 60 kilodaltons (kDa) (Nandi and Lunte, 2009), making microdialysis a well-established method for monitoring virtually any low molecular weight analyte, such as amino acids or biogenic monoamines in the extracellular space, with high sensitivity.

Microdialysis permits multimodal studies combining neural activity recording and manipulation with sample collection and neurochemical detection. Retrodialysis is used in neuropharmacological studies, where adding a pharmacological compound into the perfusate allows for simultaneous steady-state drug delivery to the tissue and sample collection from the extracellular fluid (Höcht et al., 2007). A single probe can further be used for microdialysis in conjunction with other neural recording techniques such as single cell recording or EEG (Ludvig et al., 1994; Obrenovitch et al., 1993). Quiroz and colleagues demonstrated the utility of a novel optogenetic-microdialysis probe to optically stimulate and measure glutamate and dopamine release in the posteromedial nuclear accumbens shell (Quiroz et al., 2016). Al-Hasani and colleagues have also developed an opto-dialysis probe to measure optically evoked, picomolar release of dynorphin and enkephalins in the nucleus accumbens shell in awake, freely moving mice (Al-Hasani et al., 2018). The work that has been done to allow for multimodal recording of brain activity with these new probes have further modernized the use of microdialysis to answer emerging questions in neuroscience.

2.2. Limitations and optimization

Despite its many advantages, traditional microdialysis methods suffer from low temporal and spatial resolution. While the release and uptake kinetics of many major neurotransmitters occur on the subsecond timescale, the temporal resolution of detecting small molecule neuromodulators using microdialysis is limited to the seconds to minutes timescale compared to the subsecond resolution of FSCV or fluorescence imaging. It is therefore unsurprising that microdialysis is not well-suited for detecting fast changes in neurotransmitter concentration, such as during synaptic transmission. The temporal resolution of microdialysis comes hand-in-hand with the chemical sensitivity of the system. For analytes with low physiological concentrations, such as neuropeptides,
concentrations in dialysate drops markedly due to fractional recovery rates and the dilution of analyte in perfusate that naturally occurs during microdialysis. Furthermore, large molecular weight analytes like neuropeptides yield lower relative recovery rates than those of smaller analytes (Plock and Klatt, 2005). Increased sampling times are needed for detection of high molecular weight neurochemicals, or those present in the picomolar to nanomolar range of concentrations, lending to a reduction of temporal resolution to the minutes timescale.

Work has been done to improve the temporal resolution of neurotransmitter detection using microdialysis by improving chemical sensitivity (Reinhoud et al., 2013; Zhang et al., 2012). Cyclodextrins and antibodies to capture neuropeptides have been used to reduce sampling time for neuropeptide detection (Fletcher and Stenken, 2008). Schmerberg and Li used antibody-coated magnetic nanoparticles to reduce the time needed (and obviate the need for preconcentration) to detect 31 neuropeptides after a 30 min sample collection in the Jonah crab (Schmerberg and Li, 2013). Given the release kinetics of neuropeptides, more work is needed to improve the temporal resolution of neuropeptide detection with microdialysis. Sensitivity and temporal resolution for detecting neuropeptides suffers further due to its nature to “stick” to probe and sample tube surfaces. Therefore, work to reduce the adsorption of neuropeptides has been done to aid in improved recovery and thus sensitivity (Maes et al., 2014; Zhou et al., 2015).

Dialysate analysis can occur offline after all samples are collected, or online, where dialysate is immediately directed for separation and analytical processing, allowing for “real-time” readout of neurochemical levels. Online microdialysis minimizes the possibility for sample loss or degradation after collection that may happen during offline microdialysis (Nandi and Lunte, 2009). The temporal resolution of online microdialysis is thus limited by the time needed not only for sample collection, but also chemical analysis. In the past decade, much work has been done to improve the temporal resolution of online microdialysis to sub-minute resolution (Ngo et al., 2017; Schultz and Kennedy, 2008; Song et al., 2012; Yang et al., 2013). Traditional microdialysis results in temporal averaging of concentration data due to the “binning” of dialysate into collected fractions (Ngernsutivorakul et al., 2018a). A strategy developed to combat this collects samples in nanoliter sized droplets using segmented-flow microfluidics before chemical analysis, resulting in further improvements in temporal resolution from minutes to seconds (Ngernsutivorakul et al., 2018a; Song et al., 2012).

As mentioned previously, the surface area of the probe membrane can affect the relative recovery of the probe. Although having a larger surface area can lead to improved recovery and thus potentially improved chemical sensitivity, increased probe size decreases spatial resolution. Commercial microdialysis probes can range from 200 μm in diameter and 0.5 to 4 mm long for commercially available probes to smaller microfabricated push-pull probes that are around 70 μm thick and 85 μm wide at the tip (Kennedy, 2013). Traditional probe diameters of 200 to 400 μm do not lend themselves to cellular or subcellular resolution. Additionally, a large probe size increases tissue damage leading to ischemia, gliosis, and cell death at the insertion site (Jaquins-Gerrstl and Michael, 2009). Recent efforts to miniaturize microdialysis probes have resulted in improved spatial resolution and reduced tissue damage (Lee et al., 2016; Ngernsutivorakul et al., 2018a, 2018b). Low flow rates also result in higher relative recovery and lower invasiveness by reduced non-specific depletion of solutes; however, at a cost to temporal resolution (Chefer et al., 2009). As an alternative to microdialysis, membrane-free low-flow push-pull perfusion used with liquid chromatography-tandem mass spectrometry has been developed to yield higher relative recovery of proteins and other larger molecules with higher spatial resolution (Raman et al., 2020). Further work is needed to improve the analyte recovery, as well as spatial and temporal resolution achieved by microdialysis. However, its flexibility for multiplexed chemical detection, ability to quantify basal concentrations, and adaptability to neuropharmacological studies lends to its popularity as a widely used tool for neurochemical detection.

### 3. Electrochemical Detection with Fast Scan Cyclic Voltammetry

#### 3.1. Basic Principles and Advantages

Electrochemical detection of neurochemicals with fast scan cyclic voltammetry (FSCV) is an important technique for monitoring the dynamics of many important neurochemicals with high temporal resolution and sensitivity. Voltammetry is an analytical method by which current at an electrode is measured in response to variations in applied potential. In cyclic voltammetry, a sweep up and down a range of potentials results in currents produced by the reduction and oxidation of analytes adsorbed to the electrode surface (Fig. 3). Analyte identity is commonly determined by matching traces with the characteristic
voltammogram shape and redox potentials for a given analyte. Carbon fiber microelectrodes are commonly used in FSCV due to their low cost and wide potential window. The ability to easily microfabricate miniaturized carbon microelectrodes to reduce its spatial footprint compared to commercial microdialysis probes is another benefit. Carbon fiber electrodes are typically 5-10 μm in diameter and 50-200 μm long, thus permitting higher spatial resolution compared to that of commercial microdialysis probes (Kennedy, 2013; Rodeberg et al., 2017).

To achieve millisecond “real-time” temporal resolution, FSCV utilizes fast scanning rates on the order of hundreds of volts per second. FSCV was first reported by Millar and colleagues in 1985, where they used a scan rate of 300 V/s to monitor dopamine release and uptake in the rat striatum (Millar et al., 1985). Since then, FSCV has been frequently used to measure dopamine and other catecholamines in the brains of awake and behaving animals. FSCV is able to monitor phasic dopamine signaling with high sensitivity at a limit of detection in vitro of 8 nM (Heien et al., 2005, 2004). In conjunction with carbon-fiber microsensors, FSCV has even been used to monitor dopamine release in human Parkinson’s patients during a decision making behavioral task (Kishida et al., 2005, 2004). In conjunction with carbon-fiber microsensors, FSCV has even been used to monitor dopamine release in human Parkinson’s patients during a decision making behavioral task (Kishida et al., 2016). In addition to dopamine, FSCV has also been applied to detect serotonin in model animals as well as in human patients (Hashemi et al., 2009; Heien et al., 2004; Moran et al., 2018). FSCV can also detect other brain analytes such as other catecholamines, dopamine metabolites, adenosine, guanosine, histamine, and oxygen (Cryan and Ross, 2019; Heien et al., 2004; Park et al., 2018; Samarayake et al., 2015; Wang and Venon, 2017).

Recent advances in electrode engineering have also pushed improvements in temporal resolution and sensitivity. For example, the use of carbon nanotube fiber microelectrodes increased the temporal resolution from the approximately 100 ms of standard FSCV for dopamine detection to 2 ms (Zestos and Venon, 2018). Taylor and colleagues observed a marked increase in dopamine sensitivity as a result of applying a PEDOT graphene oxide coating on microfiber electrodes (Taylor et al., 2017). Carbon nanotube yarn microelectrodes allow for better analyte adsorption, resulting in increased sensitivity (Mendoza et al., 2020; Zestos and Venon, 2018). Dopamine trapping with cavity carbon nanopipette electrodes have allowed for signal amplification without large reductions in temporal resolution and high spatial resolution (Yang et al., 2019).

Furthermore, FSCV permits multimodal studies where neurochemical monitoring can be coupled with electrical stimulation and electrophysiological measurements. To determine the relationship between local electrical activity and changes in neurochemical concentrations, probes for simultaneous FSCV and electrophysiological recording have been developed (Hobbs et al., 2017; Owesson-White et al., 2016). Advances in voltammogram analysis, alternate waveform development (other than the traditional triangle waveform, discussion below), and specialized probes have allowed for simultaneous, multiplexed detection of different neurochemicals (Hersey et al., 2021; Rafi and Zestos, 2021a; Wang and Venon, 2017).

3.2. Challenges and optimizations

One of the major limitations of FSCV is poor molecular specificity. The identity of a chemical is determined by the shape of the resultant oxidation curve and redox peak locations. Applying the traditional triangle waveform for detecting dopamine yields similar voltammograms for dopamine and norepinephrine, making it difficult to distinguish between changes in the two analytes (Heien et al., 2003). There is also similarity in the voltammograms of dopamine metabolites DOPAC to 3-MT and L-DOPA, as well as similar redox potentials between serotonin and dopamine or its metabolite 5-hydroxyindole acetic acid (5-HIAA) (Hashemi et al., 2009; Heien et al., 2004; Moran et al., 2018).

There are several strategies that have been developed to improve chemical selectivity. Principal components regression is the main method for FSCV data analysis, which is used to identify distinct features of voltammograms and compare them against training sets of voltammograms of known analyte identity and concentration (Pathongkham and Venon, 2020). Several groups have developed supervised machine learning approaches to discriminate between changes in serotonin and
Electrode coatings to reduce the accumulation of metabolites and redox side products can also increase chemical selectivity by preventing analytes with similar redox profiles from adsorbing to the electrode surface. For example, Nafion coated electrodes have been used to prevent fouling of carbon fiber electrodes by 5-HIAA whose similarities to serotonin would reduce recording specificity and fidelity (Hashemi et al., 2009). Developments in using alternative waveforms other than the traditional triangle waveform has been an inexpensive and easily implemented method to get around chemical selectivity issues (Puthongkham and Venton, 2020; Raffi and Zestos, 2021b). For example, using a square wave or staircase waveform can increase the sensitivity and selectivity for detecting dopamine to differentiate from other catecholamines (Park et al., 2016). Notably, the development of the “sawhorse” waveform has been used to increase the selectivity of adenosine detection, and has been optimized to be used to detect neuropeptides leu and met-enkephalins with FSCV (Calhoun et al., 2019; Ross and Venton, 2014).

Another limitation of FSCV is that it can only directly measure electroactive neurochemicals, limiting the range of chemicals that can be probed. However, functionalization of electrodes has allowed for improvements in the breadth of chemicals that can be detected via FSCV. For example, carbon fiber microelectrodes have been enzyme-modified to convert glucose or L-lactate into the electroactive species $\text{H}_2\text{O}_2$ that can be detected by FSCV (Forderhase et al., 2020; Lugo-Morales et al., 2013; Smith et al., 2017).

FSCV requires the implantation of a large probe that is prone to biofouling, which can reduce the fidelity of chronic recordings in freely moving animals. An additional challenge is that the faradic current resulting from the redox of analytes on the electrode is extracted upon subtraction of the background current, which can be problematic for chronic recording in brain regions where fluctuations in the background charging current itself is likely to occur. Several factors can result in fluctuations in the background current, including pH changes in the local environment and biofouling of the electrode due to non-specific adsorption of redox by-products and metabolites to the electrode. Inflammation at the site of implantation can result in immune cell encapsulation of microsensors, effectively increasing the impedance of the electrode and also causing shifts in background current (Kozai et al., 2015; Seaton et al., 2020). These factors reduce the sensitivity of FSCV over repeated electrode use (Bennet et al., 2016; Kozai et al., 2015; Takmakov et al., 2010).

Several groups have been working on developing alternative electrode coatings and materials to curb electrode fouling, thus improving compatibility with chronic recording. Bennet and colleagues developed a diamond-based electrode for chronic FSCV in deep brain stimulation devices for implantation in patients (Bennet et al., 2016). Polymeric coatings for electrodes have been engineered to prevent nonspecific molecule adsorption to electrodes (Feng et al., 2019b; Liu et al., 2017; Puthongkham et al., 2019). Advances in FSCV protocols have also been pursued to improve electrode sensitivity in chronic recordings. Seaton and colleagues developed a three electrode system to combat increases in local dopamine levels that result from changes in fluorescence of these small molecules can report exocytosis and thus neurotransmitter release (Dunn et al., 2018; Rodríguez et al., 2013). FFNs are well suited for imaging neurotransmitter dynamics at the scale of individual synapses in dissociated neuronal culture and in brain slice, and have been used to image cortical norepinephrine dynamics in vivo (Dunn et al., 2018). It can also be used for high-throughput pharmacology bioassays to identify new inhibitors for monoamine transporters (Bernstein et al., 2012).

Near-infrared sensors based on carbon nanotubes are engineered by sonicing single wall carbon nanotubes with oligonucleotides and can be evolved to specifically bind to analytes of interest (Jeong et al., 2019; Yang et al., 2021). Near-infrared fluorescent neurotransmitter sensors (nIRCatS) detect dopamine release in striatal slices elicited by electrical stimuli (Beyene et al., 2019; Yang et al., 2021). Near-infrared 5-HT probes (nIRHT) can detect exogenous 5-HT in acute brain slices (Jeong et al., 2019). The near-IR spectrum provides flexibility for simultaneous imaging with other dyes, sensors, and optogenetic tools in the visible spectrum. Additionally, the nanosensors are compatible with both genetically tractable and intractable organisms, making them easy to use and potentially compatible for human applications. Some other advantages nIRCatS offer over genetically-encoded fluorescent indicators are they: 1) do not need viruses to express the sensor, 2) do not need time for cells to express the sensors, and 3) do not photobleach and are photo-stable (O’Connell et al., 2002; Yang et al., 2021). However, these sensors are not able to distinguish between dopamine and norepinephrine, and thus further optimization is needed to improve chemical specificity. In addition, application in vivo has yet to be seen.

Though chemical probes allow for sensitive detection of synaptic dopamine concentrations from their FSCV recordings (Bang et al., 2020; Moran et al., 2018). Microdialysis has high chemical resolution and sensitivity towards many analytes, it has limited temporal resolution. In contrast, FSCV has high temporal resolution (<100 ms) and sensitivity, but limited chemical selectively that many recent efforts have been made to ameliorate. Advances in probe engineering have resulted in reduced FSCV probe sizes and reductions in biofouling. Future work will only further improve the applicability of both FSCV and microdialysis for sensitive chronic recording applications.

4. Fluorescence imaging of neurotransmitter and neuromodulator release

Synaptic transmission is a complex event that can be better accessed optically. Fluorescence imaging with advanced microscopy and an array of synthetic and genetically encoded sensors have become broadly utilized technology in modern neuroscience due to their accessibility, high molecular and cell-type specificity, and high spatiotemporal resolution. Here, we focus on discussing fluorescence sensors that can permit direct measurement of neurotransmitters and neuromodulators in real-time.

4.1. Non-genetically encoded neurochemical probes

Chemical dyes and nanomaterials are rich resources for developing new fluorescence probes. Fluorescent false neurotransmitters (FFN) are synthetic fluorescent neurotransmitter analogs that can trace the accumulation and release of dopamine, norepinephrine, and serotonin with single synapse resolution (Dunn et al., 2018; Henke et al., 2018; Post and Sulzer, 2021). FFNs undergo vesicular loading and release with native neurotransmitters by binding to specific neurotransmitter transporters, such as VMAT2, DAT, NET, and SERT (Gubernator et al., 2009; Henke et al., 2018). FFNs can be especially valuable for analysis of the heterogeneity of presynaptic sites. For example, FFN200 is a VMAT2 substrate that can specifically label dopaminergic neurons (apart from serotoninergic neurons) in the striatum, and can report silent dopaminergic vesicle clusters when used in conjunction with endocytic marker FM1-43 (Pereira et al., 2016). By tuning the pH sensitivity of FFNs, changes in fluorescence of these small molecules can report exocytosis and thus neurotransmitter release (Dunn et al., 2018; Rodríguez et al., 2013). FFNs are well suited for imaging neurotransmitter dynamics at the scale of individual synapses in dissociated neuronal culture and in brain slice, and have been used to image cortical norepinephrine dynamics in vivo (Dunn et al., 2018). It can also be used for high-throughput pharmacology bioassays to identify new inhibitors for monoamine transporters (Bernstein et al., 2012).
neurochemical dynamics and a broad range of potential applications in model animals and potential compatibility in humans, they do not offer information about cell-type specificity and may thus require post hoc immunostaining or parallel utilization of genetic labeling tools for increased specificity (Pereira et al., 2016).

4.2. Genetically Encoded Fluorescent Indicators for Neurotransmitters and Neuromodulators

In the past decade, the development and refinement of fluorescent genetically encoded calcium and voltage indicators (Abdelfattah et al., 2019; Baird et al., 1999; Carandini et al., 2015; Chen et al., 2013; Dana et al., 2011; Miyawaki et al., 1997; Nakai et al., 2001; Piatkevich et al., 2019; Tian et al., 2009; Villette et al., 2019; Yang et al., 2018; Zhao et al., 2011) has advanced capabilities in sensor design, optimization, characterization, and validation, as well as improved our understanding of how to apply these tools in behaving animals. This know-how paved the way for the development of genetically encoded indicators (GEIs) for neurotransmitters, neuromodulators, and neuropeptides (Table 1).

The basic design principle of fluorescent biosensors for neurochemical detection is to couple ligand-induced conformational changes of a ligand binding domain to the fluorescent intensity changes of the reporter domain, thus providing an optical readout of chemical transients. The reporter element typically employs either a single fluorescent protein (FP) or a FRET pair of donor and acceptor FPs. Upon ligand binding, conformational change in the recognition element leads to changes in fluorescence intensity of a single FP or FRET between two FPs. Upon genetic encoding for glutamate, the predominant excitatory neurotransmitter in the brain, are one of the earliest developed for imaging in the brain. FLIPE is the first engineered glutamate sensor with an affinity (measured by $K_d$) of 600 nM, by fusing FRET pairs with bacterial glutamate periplasmic binding protein (PBP) YbeJ/Glh (Okumoto et al., 2005).

Table 1
Summary of significant genetically encoded indicators for monitoring neurotransmitters.

<table>
<thead>
<tr>
<th>Sensor</th>
<th>Target analyte</th>
<th>PBP or GPCR</th>
<th>Single FP or FRET pair</th>
<th>$K_d$ (μM)</th>
<th>Off-target analytes</th>
<th>Other spectral variants/FP</th>
<th>Further iterations (with improved affinity, kinetics, or dynamic range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLIPE-600n</td>
<td>Glutamate</td>
<td>PBP</td>
<td>ECFP, Venus</td>
<td>0.63 $^a$</td>
<td>Aspartate, Glutamate, Asparagine</td>
<td>FLIPE-10 u, FLIPE-100 u, FLIPE-1 m</td>
<td>FLIPE-HPE-1 u (Deuschle et al., 2005)</td>
</tr>
<tr>
<td>superGluSnFr</td>
<td>Glutamate</td>
<td>PBP</td>
<td>ECFP, Citrine</td>
<td>2.5 $^c$</td>
<td>Aspartate, Glutamine</td>
<td>SF-Venus/GluSnFr / cpVenus (Marvin et al., 2018)</td>
<td>SF-iGluSnFr A184S, SF-iGluSnFr S72A (Marvin et al., 2018)</td>
</tr>
<tr>
<td>iGluSnFr</td>
<td>Glutamate</td>
<td>PBP</td>
<td>cpGFP</td>
<td>4.9 $^c$</td>
<td>Aspartate</td>
<td>DF-Light1 / cpFP (V203Y, S72A), RdLight1 / cpFP (Patriarchi et al., 2020)</td>
<td>dfLight1.2, dfLight1.3, dfLight1.4</td>
</tr>
<tr>
<td>iGABASnFr</td>
<td>GABA</td>
<td>PBP</td>
<td>cpSGFP</td>
<td>30 $^c$</td>
<td>Alanine, Glycine, Histidine</td>
<td>grGRABaB1a, grGRABaB1b / cpFP (Sun et al., 2020)</td>
<td>grGRABaB2a, grGRABaB2b (Sun et al., 2020)</td>
</tr>
<tr>
<td>GlyFS</td>
<td>Glycine</td>
<td>PBP</td>
<td>ECFP, Venus</td>
<td>21.4 $^d$</td>
<td>Leucine, Valine, Threonine</td>
<td>YdLight1 / cpFP (V203Y, S72A), RdLight1 / cpFP (Patriarchi et al., 2020)</td>
<td>dfLight1.2, dfLight1.3, dfLight1.4</td>
</tr>
<tr>
<td>dLight1.1</td>
<td>Dopamine</td>
<td>GPCR</td>
<td>cpGFP</td>
<td>0.33 $^b$</td>
<td>Norepinephrine, Epinephrine</td>
<td>rGRABaB1a, rGRABaB1b / cpFP (Sun et al., 2020)</td>
<td>grGRABaB2a, grGRABaB2b (Sun et al., 2020)</td>
</tr>
<tr>
<td>GRaB5a</td>
<td>Dopamine</td>
<td>GPCR</td>
<td>cpGFP</td>
<td>0.13 $^b$</td>
<td>Norepinephrine</td>
<td>rGRABaB1a, rGRABaB1b / cpFP (Sun et al., 2020)</td>
<td>grGRABaB2a, grGRABaB2b (Sun et al., 2020)</td>
</tr>
<tr>
<td>iSerotoninFr</td>
<td>Serotonin</td>
<td>PBP</td>
<td>cpGFP</td>
<td>0.0263 $^b$</td>
<td>5-HT2AR agonists</td>
<td>No significant response</td>
<td></td>
</tr>
<tr>
<td>psychLight</td>
<td>Serotonin</td>
<td>GPCR</td>
<td>cpGFP</td>
<td>0.022 $^c$</td>
<td>No significant response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRaB2AT</td>
<td>Serotonin</td>
<td>GPCR</td>
<td>cpGFP</td>
<td>0.022 $^c$</td>
<td>No significant response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRaB2a</td>
<td>Norepinephrine</td>
<td>GPCR</td>
<td>cpGFP</td>
<td>1.9 $^c$</td>
<td>Dopamine, Epinephrine, a2AR agonists</td>
<td>No significant response</td>
<td>GAcH3.0 (Jing et al., 2020)</td>
</tr>
<tr>
<td>GAcH2.0</td>
<td>Acetylcholine</td>
<td>GPCR</td>
<td>cpGFP</td>
<td>0.4 $^c$</td>
<td>Choline, Serotonin, Nicotine, Oxytremorine</td>
<td>Y-1AcchSnFr / Venus</td>
<td></td>
</tr>
<tr>
<td>iAchSnFr</td>
<td>Acetylcholine</td>
<td>PBP</td>
<td>cpSGFP</td>
<td>19 $^a$</td>
<td>Acetylcholine, Choline, Varenicline</td>
<td>No significant response</td>
<td>GAcH3.0 (Jing et al., 2020)</td>
</tr>
<tr>
<td>iNicSnFr</td>
<td>Nicotine</td>
<td>PBP</td>
<td>cpSGFP</td>
<td>19 $^a$</td>
<td>Acetylcholine, Choline, Varenicline</td>
<td>No significant response</td>
<td>GAcH3.0 (Jing et al., 2020)</td>
</tr>
</tbody>
</table>

$K_d$ values listed are determined in (a) purified protein, expressed in (b) HEK293T, in (c) dissociated neuronal culture, or in (d) acute hippocampal slice. (e) Only off-target analytes that elicit the same type of response as that of the target analyte were listed, i.e. for single FP sensors, off-target analytes that also cause an increase in fluorescence upon sensor binding were listed.
iGluSnFr was engineered by rational design to determine the insertion early FRET glutamate indicators (Fig. 4B) (Marvin et al., 2013). In 2008, the FRET sensor superGluSnFr improved on existing FRET glutamate sensors with increased response magnitude (changes in FRET efficiency upon glutamate binding) and operation at a more physiological range of glutamate concentrations in neuronal culture (Hires et al., 2008a). Single FP sensors, utilizing the development of circularly permuted FPs (like those used in the widely used calcium indicators GCaMP), offers many advantages to FRET sensors. Thus far, the applicability of FRET sensors for imaging neurotransmitter release is limited to use in brain slice or in dissociated neuronal culture, primarily due to the limited dynamic range of these ratiometric measurements (Hires et al., 2008a; Okumoto et al., 2005). Single FP based indicators offer several appealing advantages for in vivo application, such as superior sensitivity, enhanced photostability, broader dynamic ranges and faster kinetics compared to FRET-based indicators. Tables comparing the properties of existing single FP and FRET neurotransmitter sensors have been generated in prior reviews (Bi et al., 2021; Leopold et al., 2019). They are relatively small, and are thus relatively easier to be targeted to sub-cellular locations, such as spines and axon terminals. The preserved spectrum bandwidth of single-FP indicators can allow for multiplexed imaging or use alongside optogenetic effectors such as channelrhodopsin. iGluSnFr is the first single FP glutamate sensor, consisting of circularly permuted GFP (cpGFP) fused to YbeJ/GltI, the PBP utilized in circularly permuted GFP (cpGFP) fused to YbeJ/GltI, the PBP utilized in early FRET glutamate indicators (Fig. 4B) (Marvin et al., 2013). iGluSnFr was engineered by rational design to determine the insertion location of cpGFP into GltI near the hinge region of the protein that facilitates domain opening and closing (venus flytrap-like motion). Marvin et al. also performed site-saturated mutagenesis and high-throughput screening of the linker regions that connect cpGFP to GltI to achieve a high dynamic range sensor that they validated in neuronal culture, brain slice, and in vivo in fish, mice, and C. elegans (Marvin et al., 2013). Recent engineering efforts have led to the improvement of the brightness and affinity of iGluSnFr and expansion of available color variants (SF-iGluSnFr) (Marvin et al., 2018). Helassa and colleagues have pursued improvements to the affinity and kinetics (iGlu2, iGlu3) of iGluSnFr to enable imaging of high-frequency release in hippocampal slice (Helassa et al., 2018).

Microbial PBPs form a large protein superfamily that bind numerous classes of small molecules and peptides. Ligand binding in PBPs induces a large venus flytrap-like conformational change, which is highly conserved. These unique features have been used to develop a toolkit of highly sensitive sensors for other neurochemicals, including GABA (iGABA-SnFr), ATP (iATPSnFr), acetylcholine (iAchSnFr) and nicotine (iNicSnFr) (Borden et al., 2020; Lobas et al., 2019; Marvin et al., 2019; Shivange et al., 2019). However, there are several analytes for which bacterial PBPs do not exist. We recently developed the PBP-based sensor iSerotoninSnFr for serotonin, which does not naturally have any known associated PBPs. We used machine learning guided evolution of an existing PBP-based sensor, iAchSnFr (Borden et al., 2020), to redesign its binding pocket to report serotonin release at physiological concentrations (Unger et al., 2020). We utilized iSerotoninSnFr to detect serotonin in cultured neurons, brain slice, and for detecting behaviorally triggered serotonin release in mice using fiber photometry (Unger et al., 2020).

As an alternative to PBP-based sensors, recently, sensors for monoamine neurotransmitters have been developed by fusing eukaryotic G-protein-coupled receptors (GPCRs) with fluorescent reporters. As the endogenous receptors of neurochemicals, GPCRs have the evolved affinity and specificity relevant to binding of neurochemicals released at physiological concentrations. The first generation of GPCR-sensors were FRET-based and were mostly applied in cultured neurons to study receptor kinetics (Hoffmann et al., 2005; Jensen et al., 2009; Maier-Peschel et al., 2010; Vilardaga et al., 2003). However, use of these sensors in vivo has been limited due to low dynamic range and sensitivity (Leopold et al., 2019; Bi et al., 2021). The iTango biosensor was developed to amplify the signal produced by ligand binding to induce gene expression via β-arrestin signaling, labeling cells that have

![Fig. 4.](image-url) (A) Schematic of action of FRET glutamate sensor FLIPE (Okumoto et al., 2005). FLIPE consists of FRET pairs CFP and YFP (Venus) that reduces in FRET efficiency upon glutamate binding to GltI. (B) Schematic of iGluSnFr, which increases in fluorescence upon glutamate binding (Marvin et al., 2013). (C) Schematic of a generalized GPCR sensor that contains a GPCR with cpGFP fused to IL3. Ligand binding induces a conformational change in the GPCR that results in an increase in fluorescence.
undergone GPCR activation (Barnea et al., 2008; Smith et al., 2017). However, the poor temporal resolution of an hour or more for signal amplification and expression and the irreversible nature of this system necessitated GEIs that can capture the fast dynamics of neurochemical release. To overcome these barriers, single-FP based GPCR sensors have been recently developed.

GPCRs have seven transmembrane (TM) alpha helices, where the largest conformational change upon activation is thought to occur for TM domains 5 to 7 (Latorraca et al., 2017). Thus far, cpFPs have been inserted in the intracellular loop 3 (IL3) domain of GPCRs, which bridges TM5 and TM6, to detect this conformational change upon ligand binding (Fig. 4C). Using this versatile strategy, our lab developed the Light sensor family, consisting of dopamine, norepinephrine and serotonin sensors by inserting cpGFP into human GPCRs, including DRD1, 2, or 4, β2AR and 5-HT2A receptors (Dong et al., 2021; Patriarchi et al., 2018). Through linker screening by site-directed mutagenesis, we engineered high affinity, fast indicators that were amenable to recording dopamine release. To overcome these barriers, single-FP based GPCR sensors have been developed with the engi

5. Challenges for neurochemical monitoring with genetically encoded indicators

5.1. Mesoscopic and microscopic views of neurotransmitter and neuromodulator release

A major advantage of neurochemical monitoring using genetically-encoded sensors is that it permits long-term recording where the same cells can be revisited and imaged over the timescale of days to months (Chen et al., 2012). The transgene that encodes the fluorescent indicator is typically delivered via targeted or systemic injection of adeno-associated virus (AAV) and its derivatives (e.g. AAV-PHP.eB), followed by a few weeks of expression before imaging. In addition, genetic tools like Cre/loxP, Flp/FRT, and the Gal4/UAS system can be utilized for imaging modalities to neurotransmitter or neuromodulator sensors in vivo and ex vivo (Patriarchi et al., 2018). Parallel work in dopamine GEI engineering has been carried out with the engineering of the GRAB-DA sensors using DRD2 as the scaffold (Sun et al., 2020, 2018). Jing and colleagues developed the GACe family of sensors by inserting cpGFP in a chimeric muscarinic acetylcholine receptor (M2R) with an IL3 domain derived from β2AR (Jing et al., 2018). Dürst and colleagues (Dürst et al., 2019) have tethered iGluSnFr to full length, to the Light series, GRAB sensors have also been expanded to norepinephrine, serotonin, and adenosine, and implemented in culture, slice, and in behaving rodents (Feng et al., 2019a; Fan et al., 2021; Wu et al., 2020).

5.2. Optimizing the intrinsic properties of sensors

Synaptic release and uptake occur on the millisecond timescale whereas spillover and volume transmission occur at longer time scales, necessitating sensors with kinetics at various physiological time scales. Most single-FP GEIs for imaging neuromodulators have sub-second on- and off-rates (Sabatini and Tian, 2020). As previously mentioned, ultrafast variants of iGluSnFr (τoff of 460 μs, τon of 2.6 ms μs for iGluSnFr) have been engineered to image the fast dynamics of high frequency (100 Hz) glutamate release in organotypic slice culture (Helassa et al., 2018). A limitation to further improving sensor kinetics is the nature of fluorescence generation using cpFPs after ligand binding. Reconstitution of the fluorescent complex (may it be two parts of a PBPP sensor or bringing together GPCR strands) and subsequent conformational change is first needed before fluorescence modulation (Helassa et al., 2018). The temporal resolution for GEIs is thus limited by the timescale of ligand binding domain rearrangement and transduction to the fluorescent reporter.

Although using natural receptors should allow for high sensitivity detection, to view single quanta release with high SNR and lower the limit of detection of GEIs, further engineering is often needed. The sensitivity of these sensors is determined by the dissociation rate and dynamic range, and can be altered by basal ligand concentrations. High SNR sensors, however, may come at a cost to temporal resolution, as sensors with slow decay kinetics allow for more time for photon detection. Engineering GEIs with large changes in fluorescence in response to even low levels of an analyte of interest, often achieved by linker screening, is critical for low limits of detection for in vivo imaging. High affinity variants of Gln, the PBP involved in iGluSnFr, have been screened and explored by several groups in order to improve the detection limits of glutamate sensors (Helassa et al., 2018; Hires et al., 2009b; Marvin et al., 2018). Creating high affinity sensors with slow off kinetics and high expression, however, could result in ligand buffering effects and disruption of endogenous activity. Negative physiological effects as a result of ligand buffering and calcium dysregulation due to calcium GEI expression, including versions of GCaMP, have been reported in several studies (Gastersstädt et al., 2020; McMahon and Jackson, 2018; Steinmetz et al., 2017; Yang et al., 2018). It has become more of the standard to express GEIs under the relatively weak neuronal...
specific synapsin promoter to curb these potential effects. Further efforts in sensor engineering will be needed to ensure minimal disruption to host processes. For example, GCaMP-X was engineered based on the findings that GCaMP was shown to disrupt endogenous voltage-gated calcium channel function by causing calcium dysregulation (Yang et al., 2018). iGluSnFr has also been found to compete with glutamate transporters and have buffering effects, so sensor engineering efforts must be made to curb this disruption of endogenous activity (Arbruster et al., 2020).

The use of naturally occurring receptors or designed binding proteins as scaffolds affords for high chemical selectivity; however, binding to off-target analytes, especially to structurally related molecules can potentially complicate studies where multiple neurotransmitter release mechanisms are expected (Table 1). Glutamate sensors like FLIPE and iGluSnFr can respond to both glutamate and aspartate binding (Marvin et al., 2013; Okumoto et al., 2005). iGABASnFr can respond to glycine and AChSnFr can detect choline and nicotine (Borden et al., 2020; Marvin et al., 2019). Previously, we discussed how FSCV can yield similar voltamograms for dopamine and structurally similar norepinephrine and epinephrine. Similarly, GRAB-DA and dLight can also respond to norepinephrine (Patriarchi et al., 2018; Sun et al., 2020), although with reduced affinity. For example, dLight has 70 fold and 40-fold lower affinity for norepinephrine and epinephrine, respectively, to dopamine (Patriarchi et al., 2018). It is likely that for future sensors that are able to bind nonspecifically to structurally related analytes, binding pocket engineering like that undergone to engineer iSoRoSnFr can reduce nonspecific binding affinity (Unger et al., 2020). A further limitation for GPCR-based sensors is their ability to respond to drug modulation that may target that specific receptor. While this may make this class of sensors difficult for studies that seek to measure drug-mediated changes in neurochemical release, it can also be an added benefit. In our recent work, we demonstrated that psychLight has applications in not only in vivo detection of serotonin release, but also as a tool for predicting the hallucinogenic potential of known and novel psychoplasticogenic compounds in vitro (Dong et al., 2021).

Simultaneous detection of different neurochemicals with biosensors are relatively challenging compared to microdialysis because of the need to avoid spectral overlap. The majority of well-characterized single FP GEIs use GFP, though in the past few years, efforts have been made to develop red-shifted versions of sensors that need further development for widespread in vivo use (Table 1). Different color variants of fluorescent GEIs will allow for flexibility with not only other sensors for simultaneous analyte detection, but also with other optogenetic actuators. Beyond fluorescent protein based GEIs, hybrid far-red calcium and voltage indicators based on the self-labeling protein HaloTag have been developed (Abdellattah et al., 2019; Deo et al., 2021). The development of orthogonal fluorescent GEIs with different mechanisms of action, color variants, and targets will allow us the flexibility to answer even broader range of neuroscience questions.

A disadvantage of GEIs that is shared with FSCV is their inability to determine absolute basal concentrations of an analyte of interest. While relative changes in concentration can be calculated from changes in fluorescence by referring to dose-response curves, basal concentrations cannot be estimated with intensity-based indicators, though it has been attempted with FRET sensors, for example using the glycinic sensor GlyFS (Zhang et al., 2018). Perhaps the development of fluorescent lifetime-based indicators, such as a recent calcium indicator released by van der Linden and colleagues, could allow for quantification of basal analyte concentrations (van der Linden et al., 2021).

5.3. Challenges in image analysis

Single FP sensors utilize the metric dF/F₀, where measurements of the change in fluorescence intensity are normalized by baseline fluorescence intensity (F₀) to quantify changes in analyte concentration. However, several factors can interfere with accurately converting dF/F₀ to changes in concentration. For example, sensor aggregation due to high sensor expression would invariably result in diluted apparent dF/F₀ values. Furthermore, as fluorescence values are normalized by a “baseline” fluorescence intensity for a period of time before the event of interest, drifts in conditions that cause baseline fluorescence values to shift irrespective of analyte levels would interfere with accurate quantification. Sample movement, photobleaching, and pH sensitivity can all result in changing baseline levels throughout the course of an experiment. The consequences of having a noisy F₀ and a suggestion for data quantification in light of this is discussed in a recent work (Sabatini and Tian, 2020).

A further challenge for consistent reporting of neurochemical dynamics between different studies is the lack of standardization in image processing and analysis techniques. In vivo imaging with neurotransmitter sensors presents many challenges, including diffuse membrane and neuropil expression, motion artifacts from imaging freely moving animals, and high autofluorescence and low sensor signal with the use of minimal laser power to minimize photodamage to the tissue and reporter bleaching. Multiplespectral imaging can be used to unmix autofluorescence in vivo since the spectrum of objects contributing to autofluorescent background are often broader than the fluorescent markers (Mansfield et al., 2005). However this can be complicated by the many variable sources of autofluorescence in a tissue, which makes it difficult to determine the spectral properties of all components in the sample required for accurate automated unmixing (Mansfield et al., 2005). Additionally, uneven fluorescence illumination and detection across a field of view makes it difficult to accurately and precisely quantify fluorescence (Kozloski and Weimer, 2012). Therefore, considerations for region of interest (ROI) selection, background subtraction, and motion artifact correction are important. For example, different methods for ROI determination for measuring mean fluorescence have been utilized for in vivo and ex vivo use of established neurotransmitter sensors, ranging from whole frame ROIs to ROIs obtained by manual selection or automatic segmentation (Marvin et al., 2013; Patriarchi et al., 2018; Sun et al., 2018). Each technique can result in different dF/F₀ results and consistency issues when comparing results from different groups utilizing the same sensor. The measured fluorescence changes from whole frame ROIs are diluted by background pixels with no sensor expressed, thus making the magnitude of fluorescence changes dependent on both noise from background and on sensor expression levels within a field of view. Meanwhile, segmenting an image to restrict measurement to areas of sensor expression can be a work-around for low SNR images and will minimize the “dilution” effect of fluorescence changes when including background pixels where no sensor is expressed.

While much work has been done to develop open-source image analysis software for in vivo calcium imaging (Cantu et al., 2020; Giovannucci et al., 2019; Tegtmeyer et al., 2018), the inherent differences between intracellularly expressed calcium indicators and synaptic and membrane targeted transmitter sensors may limit their translatability. Detecting and quantifying neurochemical release at the level of individual synapses has been explored (Dürst et al., 2019; Farzi et al., 2021), and perhaps recent advances in synapse detection algorithms for fluorescent images may further improve the accessibility and accurate quantification of synaptic release analysis using GEIs (Feng et al., 2012; Kulikov et al., 2019; Wang et al., 2019). An open-source software suite (pMAT) for analysis of fiber photometry data has been recently developed, allowing for implementation of a standardized data analysis pipeline across groups (Bruno et al., 2021). As isosbestic points for various sensors could vary, further development can be done to accommodate signal normalization based on other spectra. Nonetheless, there is a need for new open-source tools for automated analysis of longitudinal imaging with neurotransmitter GEIs with microscopic applications.
6. Outlook

We are in a new and exciting era of neurochemical recording. Emerging questions proposed by neuroscientists and lessons learned in creating a variety of technologies will serve as the nexus for the development of novel neurochemical probes. Besides techniques discussed above, other chemical and cell-based approaches have also been developed to monitor neurochemical dynamics. Though fluorescence imaging provides high spatiotemporal resolution, it is not compatible with human applications. Positron emission tomography (PET) and magnetic resonance imaging (MRI) using nuclear medicine or genetically encoded probes provide information at the whole-brain level and have been broadly used for diagnosis in humans, albeit with poor spatial and temporal resolution (Finnema et al., 2015; Li and Jasanoff, 2020; Shimojo et al., 2020). The development of cell-based neurotransmitter fluorescent engineered receptors (CNIFERs) is another detection method for dopamine, norepinephrine and neuropeptides (Muller et al., 2014). CNIFERs are cells that express GPCRs that are activated upon ligand binding, resulting in calcium influx and a change in fluorescence in the FRET-based calcium reporter TN-XXL. This technique, though, requires the invasive implantation of cells and lacks the cell-type or subcellular specificity of genetically encoded indicators. Aptamers, single stranded oligonucleotides that fold into 3D structures, have been engineered to bind neurochemicals with high sensitivity and specificity (Ellington and Szostak, 1990; Gold et al., 1995). Aptamers have been used for electrochemical biosensors to detect the rearrangement of aptamer structure as a result of ligand binding, and have potential for sensitive and specific neurochemical detection in vivo in the near future (Nakatsuka et al., 2018).

Neurochemicals are substantially diverse (e.g. more than 100 known neurotransmitter/modulators), contributing to the myriad of inputs and signals to neural circuits (Kovász, 2004). Together with heterogeneity within cell types, it is a grand challenge to elucidate circuit mechanisms and function. Fluorescence imaging using GEIs permits cell-type specific measurement of diverse signaling inputs and post-synaptic activity, as well as provides a cellular map of neurochemical transients across the full-course of behavior, which is difficult to achieve with analytic or electrochemical methods (Table 2). Combined with optogenetic and chemogenetic actuators, we can specifically tease apart the input-output interactions within neural circuits.

However, the breadth and range of chemicals that can be detected is limited by the availability of engineered indicators. Spectral overlap between indicators also enforces limitations on multiplexing. Microdialysis, on the other hand, can simultaneously detect many compounds with sensitive chemical analysis methods. Its capability and flexibility for temporal averaging can be useful for studies where monitoring short timescale dynamics is not desired, such as to measure slow volume transmission of neuropeptides or signal integration dynamics (Table 2).

Non-invasive or minimally invasive monitoring of neurochemical dynamics in freely-moving animal models or even humans is still challenging. Probe implantation, may it be carbon fiber microelectrodes, microdialysis probes, or fiber photometry probes, can result in initiation of inflammatory processes and tissue damage. We have discussed several methods by which these probes are being miniaturized and made more biocompatible for chronic recording applications. All the methods mentioned have been extensively implemented in model animals, including non-human primates. Notably, the flexibility of FSCV for temporal study and its relatively low invasiveness has lent to its ability to measure neurochemicals in the human brain (Bennet et al., 2016), which is likely not in the foreseeable future for fluorescence imaging using GEIs. Acute microdialysis studies have also been performed in the human brain. Beyond the probe size itself, the chemical specificity of each method can also contribute to its invasive properties. Compared to GEIs which are designed to bind and recognize specific analytes, direct sampling with microdialysis or analyte adsorption to FSCV probes are not as specific. Non-specific depletion of solutes around the probe can result in repercussions given the tightly controlled chemical environment of the brain (Chefer et al., 2009). Depleting a target of interest at a single region from FSCV or microdialysis may have less of a disruption in endogenous processes compared to potentially widespread ligand buffering effects of many cells expressing genetically encoded indicators. This will continue to be an important consideration for sensor engineers moving forward.

Acknowledgements

We would like to thank our funding sources for supporting this work, including NIHST32GM099608-10 (N.T.), NIA01AG054649-05(Y.H.), NIH U01NS099726 (A.H., M.R.), NIHU01NS115579, U01NS120820 (L.T.).

References


Table 2

<table>
<thead>
<tr>
<th>Assessment Criteria</th>
<th>Microdialysis</th>
<th>FSCV</th>
<th>Fluorescent genetically encoded indicators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical resolution</td>
<td>Wide range</td>
<td>Medium</td>
<td>Medium-high</td>
</tr>
<tr>
<td></td>
<td>detected</td>
<td>Mainly</td>
<td>Sensor engineering to tune affinities to</td>
</tr>
<tr>
<td></td>
<td>with high specificity</td>
<td>electroactive analytes</td>
<td>off-target analytes</td>
</tr>
<tr>
<td>Spatial resolution</td>
<td>Low, limited</td>
<td>Medium-high</td>
<td>High, tunable from</td>
</tr>
<tr>
<td></td>
<td>by probe size</td>
<td>by probe size</td>
<td>subcellular to</td>
</tr>
<tr>
<td></td>
<td>(≥1 mm long, 200 μm diameter)</td>
<td>(≥50 μm long, 5-10 μm diameter)</td>
<td>circuits/</td>
</tr>
<tr>
<td></td>
<td>or diameter</td>
<td></td>
<td>populations</td>
</tr>
<tr>
<td>Temporal resolution</td>
<td>Low, sub-minutes</td>
<td>Sub-second</td>
<td>Sub-second</td>
</tr>
<tr>
<td></td>
<td>to minutes</td>
<td>resolution (≥ 2-100 ms)</td>
<td>resolution, tunable</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with sensor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>engineering and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>optical system</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>High, at a cost to</td>
<td>High, lessens for</td>
<td>Medium-high,</td>
</tr>
<tr>
<td></td>
<td>temporal resolution</td>
<td>chronic recording</td>
<td>sensor engineering</td>
</tr>
<tr>
<td></td>
<td></td>
<td>because of</td>
<td>efforts to improve</td>
</tr>
<tr>
<td></td>
<td></td>
<td>biofouling</td>
<td>affinity and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>brightness</td>
</tr>
<tr>
<td>Invasiveness</td>
<td>Probe insertion</td>
<td>Miniaturized probes</td>
<td>Low, non-invasive</td>
</tr>
<tr>
<td></td>
<td>causes tissue</td>
<td>allow for</td>
<td>possible with intact</td>
</tr>
<tr>
<td></td>
<td>damage and</td>
<td>reduced tissue</td>
<td>skull imaging</td>
</tr>
<tr>
<td></td>
<td>resulting ischemia</td>
<td>damage and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>alters surrounding</td>
<td>and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>tissue activity</td>
<td>chronic recording</td>
<td></td>
</tr>
<tr>
<td>Accessibility/</td>
<td>Permits multimodal studies</td>
<td>Permits</td>
<td>Limitations on</td>
</tr>
<tr>
<td>Practicality</td>
<td>and multiplexed detection</td>
<td>multimodal studies</td>
<td>multiplexing GEIs</td>
</tr>
<tr>
<td></td>
<td>of neurochemicals</td>
<td>commercially</td>
<td>Future engineering</td>
</tr>
<tr>
<td></td>
<td></td>
<td>available</td>
<td>efforts to broaden</td>
</tr>
<tr>
<td></td>
<td></td>
<td>technology</td>
<td>palette of available</td>
</tr>
<tr>
<td></td>
<td>Needs specialized chemical analysis equipment</td>
<td></td>
<td>sensors</td>
</tr>
<tr>
<td>Model Organisms</td>
<td>Mice, rats, dogs,</td>
<td>Drosophila melanogaster,</td>
<td>Escherichia coli,</td>
</tr>
<tr>
<td></td>
<td>rabbits, hamster,</td>
<td>mouse, rats,</td>
<td>D. melanogaster,</td>
</tr>
<tr>
<td></td>
<td>Jonah crab, pigs,</td>
<td>zebras, pigs,</td>
<td>Caenorhabditis</td>
</tr>
<tr>
<td></td>
<td>rhesus macaque,</td>
<td>rhesus macaques,</td>
<td>elegans, mice,</td>
</tr>
<tr>
<td></td>
<td>humans</td>
<td>humans</td>
<td>rats, zebras,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>marmosets, rhesus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>macaque</td>
</tr>
</tbody>
</table>
N. Tjahjono et al.


Neuroscience Research 179 (2022) 65–78

N. Tjahjono et al.


